<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02388048</url>
  </required_header>
  <id_info>
    <org_study_id>LLC1215</org_study_id>
    <secondary_id>2015-000684-13</secondary_id>
    <nct_id>NCT02388048</nct_id>
  </id_info>
  <brief_title>Ofatumumab &amp; Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase II Study of the Combination of Ofatumumab and Ibrutinib Followed by Allogeneic Bone Marrow Transplant or Consolidation for Pretreated High Risk Patients With Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study to evaluate a treatment with two drugs, named Ofatumumab and Ibrutinib, in&#xD;
      patients with lymphoblastic acute leukemia who have been already treated with other&#xD;
      therapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II multicenter, non-comparative, open label study for high risk previously&#xD;
      treated patients with CLL, requiring therapy, aimed at evaluating the efficacy of the&#xD;
      Ofatumumab and Ibrutinib combination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of pretreated patients with high risk CLL who achieve a Complete Response (CR) after the induction therapy with Ibrutinib plus Ofatumumab.</measure>
    <time_frame>After 6.5 years from treatment start</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients in Complete Response (CR)/Partial Response (PR)</measure>
    <time_frame>After 28 weeks from treatment start</time_frame>
    <description>Overall response rate at the end of induction therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients without progression of the disease.</measure>
    <time_frame>At 60 months from treatment start</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients alive</measure>
    <time_frame>At 60 months from treatment start</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients without events</measure>
    <time_frame>At 60 months from treatment start</time_frame>
    <description>Event-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Minimal Residual Disease-negative Complete Responses</measure>
    <time_frame>At 28 weeks from treatment start</time_frame>
    <description>6. To estimate Minimal Residual Disease (MRD) in terms of rate of MRD-negative CRs at the end of induction therapy and after SCT or Ibrutinib maintenance therapy for patients in CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>At 6.5 years after treatment start</time_frame>
    <description>7. Safety profile and tolerability of the combination of Ofatumumab and Ibrutinib and the ibrutinib as maintenance in terms of type, frequency, severity and relationship of adverse events (AEs).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Leukemia, Lymphoblastic, Chronic</condition>
  <arm_group>
    <arm_group_label>Ibrutinib + Ofatumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBRUTINIB 420 mg PO daily in 28-day cycles for a total of 7 cycles (28 weeks).&#xD;
OFATUMUMAB 300 mg on day 1 of cycle 2 of Ibrutinib, followed by 2000 mg on D8, 15, 22 of cycle 2, D1, 8, 15, 22 of cycle 3, and Day 1 of cycle 4-7.&#xD;
After induction treatment patients with HLA identical sibling or fully matched MUD donor will be addressed to reduced intensity allogeneic bone marrow transplant, while patients without a suitable donor or who refuse the transplant procedure will receive maintenance treatment by BTK inhibitor (IBRUTINIB 420 mg PO daily in 28-day cycles). Treatment will continue until disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib + ofatumumab</intervention_name>
    <arm_group_label>Ibrutinib + Ofatumumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, age 18 years or until 65 years;&#xD;
&#xD;
          2. Confirmation of B-CLL previously treated with no more than 1 previous line of&#xD;
             treatment .&#xD;
&#xD;
          3. Risk patients with CLL defined as follows:&#xD;
&#xD;
               -  treated patients showing 17p deletion in &gt;20% of the cells by FISH, or TP53&#xD;
                  mutation or,&#xD;
&#xD;
               -  resistant (SD/PD) to fludarabine containing combination therapy or relapse within&#xD;
                  12 months from a fludarabine-containing combination therapy.&#xD;
&#xD;
          4. Active disease meeting at least 1 of the following IWCLL criteria for requiring&#xD;
             treatment:&#xD;
&#xD;
               -  Evidence of progressive marrow failure as manifested by the development of, or&#xD;
                  worsening of anemia (Hb&lt; 10 g/dL) and/or thrombocytopenia (platelets &lt;&#xD;
                  100,000/mL).&#xD;
&#xD;
               -  Massive (≥ 6 cm below the left costal margin), progressive, or symptomatic&#xD;
                  splenomegaly.&#xD;
&#xD;
               -  Massive nodes (at least 10 cm longest diameter), or progressive or symptomatic&#xD;
                  lymphadenopathy.&#xD;
&#xD;
               -  Progressive lymphocytosis with an increase of more than 50% over a 2-month period&#xD;
                  or a lymphocyte doubling time (LDT) of &lt; 6 months.&#xD;
&#xD;
               -  Autoimmune hemolytic anemia and/or immune thrombocytopenia that is poorly&#xD;
                  responsive to corticosteroids or other standard therapy.&#xD;
&#xD;
               -  One or more disease-related symptoms:&#xD;
&#xD;
               -  unintentional weight loss &gt; 10% within 6 months prior to screening;&#xD;
&#xD;
               -  significant fatigue (inability to work or perform usual activities);&#xD;
&#xD;
               -  fevers &gt;38.0°C for 2 or more weeks prior to screening;&#xD;
&#xD;
               -  night sweats for more than 1 month prior to screening.&#xD;
&#xD;
          5. Stage B or C of CLL according to Binet staging system;&#xD;
&#xD;
          6. Stage A disease fitting the criteria for treatment according to the IWCLL-NCI criteria&#xD;
             (2008) are also included.&#xD;
&#xD;
          7. WHO performance status 0-II.&#xD;
&#xD;
          8. Life expectancy ≥ 6 months.&#xD;
&#xD;
          9. Hematology values must be within the following limits:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 750/mm3 independent of growth factor support;&#xD;
&#xD;
               -  Platelets ≥100,000/mm3 or ≥ 30.000/mm3 if bone marrow involvement independent of&#xD;
                  transfusion support in either situation.&#xD;
&#xD;
         10. Biochemical values within the following limits:&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper&#xD;
                  limit of normal (ULN).&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or&#xD;
                  of non-hepatic origin.&#xD;
&#xD;
               -  Serum creatinine ≤ 2 x ULN or estimated Glomerular Filtration Rate (Cockroft&#xD;
                  Gault) ≥ 30 mL/min/1.73m2.&#xD;
&#xD;
         11. Women of childbearing potential and men who are sexually active must be practicing a&#xD;
             highly effective method of birth control during and after the study For females, these&#xD;
             restrictions apply for 1 month after the last dose of ibrutinib and for 12 months&#xD;
             after the last dose of Ofatumumab. For males, these restrictions apply for 3 months&#xD;
             after the last dose of ibrutinib. Men must agree to not donate sperm during and after&#xD;
             the study.&#xD;
&#xD;
         12. Women of childbearing potential must have a negative serum (beta-human chorionic&#xD;
             gonadotropin [β-hCG]) or urine pregnancy test at Screening. Women who are pregnant or&#xD;
             breastfeeding are ineligible for this study.&#xD;
&#xD;
         13. Sign an informed consent document indicating that they understand the purpose of and&#xD;
             procedures required for the study, including biomarkers, and are willing to&#xD;
             participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Major surgery within 3 weeks before registration.&#xD;
&#xD;
          2. Known central nervous system lymphoma.&#xD;
&#xD;
          3. History of stroke or intracranial hemorrhage within 6 months prior to registration.&#xD;
&#xD;
          4. Requires anticoagulation with warfarin or equivalent vitamin K antagonists (eg,&#xD;
             phenprocoumon).&#xD;
&#xD;
          5. Clinically significant cardiovascular disease such as uncontrolled or symptomatic&#xD;
             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of&#xD;
             Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by&#xD;
             the New York Heart Association Functional Classification.&#xD;
&#xD;
          6. Vaccinated with live, attenuated vaccines within 4 weeks of registration.&#xD;
&#xD;
          7. Known history of human immunodeficiency virus (HIV) or active Hepatitis C Virus or&#xD;
             active Hepatitis B Virus infection or any uncontrolled active systemic infection&#xD;
             requiring intravenous (IV) antibiotics.&#xD;
&#xD;
          8. Any life-threatening illness, medical condition, or organ system dysfunction which, in&#xD;
             the investigator's opinion, could compromise the subject's safety, interfere with the&#xD;
             absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue&#xD;
             risk.&#xD;
&#xD;
          9. Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In&#xD;
             addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a&#xD;
             HBDNA test will be performed and if positive the subject will be excluded. ***see&#xD;
             attached monitoring criteria for HBcAb+ and HBV DNA negative subjects.&#xD;
&#xD;
         10. Other past or current malignancy. Subjects who have been free of malignancy for at&#xD;
             least 5 years, or have a history of completely resected non-melanoma skin cancer, or&#xD;
             successfully treated in situ carcinoma are eligible.&#xD;
&#xD;
         11. Requirement for treatment with a strong CYP3A4/5 and/or CYP2D6 inhibitor.&#xD;
&#xD;
         12. Significant concurrent, uncontrolled medical condition including, but not limited to,&#xD;
             renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological, cerebral or&#xD;
             psychiatric disease which in the opinion of the investigator may represent a risk for&#xD;
             the patient.&#xD;
&#xD;
         13. Inability to swallow capsules or tablets, or disease significantly affecting&#xD;
             gastrointestinal function and/or inhibiting small intestine absorption.&#xD;
&#xD;
         14. Chronic or current infectious disease requiring systemic antibiotics, antifungal, or&#xD;
             antiviral treatment such as, but not limited to, chronic renal infection, chronic&#xD;
             chest infection with bronchiectasis, tuberculosis.&#xD;
&#xD;
         15. Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura.&#xD;
&#xD;
         16. Central nervous system involvement with CLL.&#xD;
&#xD;
         17. Subjects who have current active hepatic or biliary disease (with exception of&#xD;
             patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable&#xD;
             chronic liver disease per investigator assessment).&#xD;
&#xD;
         18. Treatment with any known non-marketed drug substance or experimental therapy within 5&#xD;
             terminal half lives or 4 weeks prior to enrollment, whichever is longer, or currently&#xD;
             participating in any other interventional clinical study.&#xD;
&#xD;
         19. Prior treatment with anti-CD20 monoclonal antibody or alemtuzumab within 3 months&#xD;
             prior to the start of therapy.&#xD;
&#xD;
         20. History of significant cerebrovascular disease in the past 6 months or ongoing event&#xD;
             with active symptoms or sequelae.&#xD;
&#xD;
               -  If HBV DNA is negative, subject may be included but must undergo at least every 2&#xD;
                  month HBV DNA PCR testing from the start of treatment during the treatment&#xD;
                  course. Prophylactic antiviral therapy may be initiated at the discretion of the&#xD;
                  investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Montillo</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Hematology, Niguarda Ca' Granda, Milan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesca R. Mauro</last_name>
    <role>Study Director</role>
    <affiliation>Department of Hematology, Policlinico Umberto I di Roma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Università degli Studi &quot;Sapienza&quot; - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia</name>
      <address>
        <city>Roma</city>
        <state>Provincia</state>
        <zip>00141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Area Vasta N. 5 Ascoli Piceno - S. Benedetto Del Tronto, Presidio Ospedaliero Av5 Osp. Gen. Prov.Le &quot;C.G.Mazzoni&quot; - Uoc Ematologia</name>
      <address>
        <city>Ascoli Piceno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuovo Record Esporta in Excel Stampa Esporta in file di testo Mostra Informazioni Record Multi edit Stato dello studio presso il centro records: 28 Record 1/28 su 28 direzione di ordinamento Centro (CIC) direzione di ordinamento Sperimentatore Pri</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL N.8 - Ospedale &quot;A. Businco&quot; - Struttura Complessa di Ematologia e CTMO</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Catania - Cattedra di Ematologia - Ospedale &quot;Ferrarotto&quot;</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pugliese Ciaccio - Presidio Ospedaliero A.Pugliese - Unità Operativa di Ematologia</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuovo Record Esporta in Excel Stampa Esporta in file di testo Mostra Informazioni Record Multi edit Stato dello studio presso il centro records: 28 Record 1/28 su 28 direzione di ordinamento Centro (CIC) direzione di ordinamento Sperimentatore Pri</name>
      <address>
        <city>Cona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia - P.O. Annunziata - A.O. di Cosenza</name>
      <address>
        <city>Cosenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico di Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS_AOU San Martino-IST-Ematologia 1-Monoblocco 11°piano- lato ponente</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnoli per lo Studio e la Cura dei Tumori- IRST</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Azienda Ospedaliera Ospedali Riuniti &quot;Papardo Piemonte&quot; P.O. Papardo</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aulss 3 Serenissima, Ospedale Dell'Angelo - Mestre - Uo Ematologia</name>
      <address>
        <city>Mestre</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Irccs &quot;Istituto Nazionale Tumori&quot; - Milano - Sc Ematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda &quot; Ca Granda&quot; - SC Ematologia Blocco SUD, Ponti Est, Scala E, 4° piano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aou Di Padova - Uo Ematologia</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sl Salerno, Presidio Ospedaliero Tortora Pagani - Ematologia</name>
      <address>
        <city>Pagani</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia con trapianto - Centro di Riferimento Regionale per le coagulopatie rare nel bambino e nell'adulto Dipart. Biomedico di Medicina Interna - A.U. Policlinico &quot;Paolo Giaccone&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cattedra di Ematologia CTMO Università degli Studi di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sezione di Ematologia ed Immunologia Clinica - Ospedale S.Maria della Misericordia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia Clinica - Azienda USL di Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asl Di Piacenza, Ospedale &quot;Guglielmo Da Saliceto&quot; - Ematologia E Centro Trapianti</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Infermi&quot;</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore - Policlinico A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi - Policlinico di Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Degli Studi Di Roma &quot;Sapienza&quot; - Dipartimento Di Medicina Traslazionale E Di Precisione - U.O.C. Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Santa Maria - Terni S.C Oncoematologia</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Mauriziano Umberto I</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia ed Ematologia S.C. Ematologia 2 A.O. Città della Salute e della Scienza di Torino San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia dell' Università degli Studi di Torino - &quot;Città della Salute e della Scienza di Torino&quot;</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 9, 2015</study_first_submitted>
  <study_first_submitted_qc>March 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2015</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Chronic</keyword>
  <keyword>High-risk</keyword>
  <keyword>ofatumumab</keyword>
  <keyword>ibrutinib</keyword>
  <keyword>Lymphoblastic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ofatumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

